All lobbying filings

Ferox Strategies

Ferox Strategies filed a Q2 report for Eli Lilly and Company on July 20, 2026, reporting $60,000 in lobbying income.

Lobbying for Eli Lilly and Company · American pharmaceutical company.

As filed: FEROX STRATEGIES for ELI LILLY AND COMPANY.

All filings by Ferox Strategies · Everything Eli Lilly and Company has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Pharmacy

Issues related to the pharmaceutical industry. Issues related to treating and reducing obesity. Issues related to drug shortages and counterfeit products.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.